Ruminant oral drench, oral powder, and medicated premix use. Halimide Veterinary Grade API enters ruminant endoparasite control programmes through oral drench, oral powder, and medicated premix lines where the active is dispersed onto a carrier before stepwise dilution into finished feed. On a production-scale ribbon blender with working volume 1200 L and fill ratio 0.62, the API is first pre-blended with colloidal silicon dioxide at 1:9 w/w for 10 min, then combined with ground corn cob carrier, microcrystalline cellulose, and lactose monohydrate. The addition rate in the oral premix is kept within 0.5–2.0% w/w, with finished feed carryover typically 20–100 g/tonne depending on target species and local maximum residue limit approvals. Manufacturing follows EU Regulation 2019/4 for medicated feed and, for shipments to the United States, 21 CFR Part 225; residual solvent control follows VICH GL18; final moisture is held below 10.0% w/w using ISO 6496:1999; microbial enumeration follows ISO 4833-1:2013. The downstream process is a three-stage geometric dilution: stage one blends the API–silica masterbatch with 5 kg carrier for 15 min; stage two extends to 50 kg in a paddle mixer at 12 rpm for 20 min; stage three transfers to a double-cone blender to complete a 1000 kg batch. Content uniformity acceptance is a coefficient of variation <5.0% per VICH GL9. The blend is sifted through a 500 µm sieve and packed into PE-lined paper sacks with headspace nitrogen purging. Finished product types include 0.5% w/w oral powder, 2.0% w/w medicated premix, and 1.5% w/v oral drench solution. A known process boundary is moisture pickup above 12.0% w/w in the carrier, which causes particle agglomeration and assay loss after 60 days at 30°C; producers therefore pre-dry corn cob to <8.0% w/w before blending.

Table 1. Comparative content uniformity data from three blending sequences used to qualify a 2.0% w/w Halimide premix.

What limits terminal sterilisation in Halimide Veterinary Grade API injectable solutions?

In cattle and sheep injectable programmes, Halimide Veterinary Grade API is formulated as a 5.0% w/v solution in a non-aqueous water-miscible system of propylene glycol 60% v/v, benzyl alcohol 1.0% v/v, and water for injection q.s. The API is dissolved at 55–60°C, cooled to 25°C, and adjusted to pH 8.0–8.5 with 1 M sodium hydroxide before making to volume. The addition ratio in the injectable concentrate is 5.0% w/v active, corresponding to 50 mg/mL, and the product is filled into 50 mL single-dose and 250 mL multidose vials under Grade C conditions with terminal sterilisation or aseptic filtration. Sterility is verified under USP <71>, bacterial endotoxins under USP <85>, particulate matter under USP <788>, and visible particulates under USP <790>; the injection route in the United States is governed by 21 CFR Part 522 approval requirements. The principal process conflict is terminal sterilisation: an autoclave cycle at 121°C for 15 min can produce a pH drift greater than 0.3 pH units and raise subvisible particles ≥10 µm when the fill volume exceeds 100 mL and stopper headspace oxygen is not purged. Aseptic filtration through a 0.22 µm PVDF membrane is therefore used for heat-sensitive batches, with a maximum hold time of 4 h between dissolution and filter integrity testing. Incompatibility is observed with chlorobutyl stoppers that have not been pre-washed; stoppers are autoclaved separately and rinsed with water for injection to reduce extractables. Finished product types are injectable solution for subcutaneous administration in cattle and sheep, supplied in multidose amber glass vials. Published data for this specific configuration is limited, so every sterilisation cycle is bracketed by pilot-scale qualification with product assay and pH drift tracked at 0, 6, and 12 months under 25°C/60% RH and 40°C/75% RH.

Table 2. Autoclave pH drift and subvisible particle formation in three Halimide injectable solvent systems.

Swine grower-finisher feed-grade granules utilise Halimide Veterinary Grade API at 1.0% w/w in a Type B medicated premix that is extended 1:50 into complete feed before pelleting. The granule line consists of a vertical high-shear granulator with an impeller speed of 150–250 rpm and a chopper speed of 1500–3000 rpm, a fluid bed dryer with inlet air at 65–75°C, and a conical mill fitted with a 1.2 mm rasping screen. The binder is povidone K30 dissolved in purified water to 5.0% w/v, added at 12.0% w/w of the dry charge; granulation endpoint is judged by an initial impeller torque increase of 15–20% over the dry mix baseline. The granulate is dried to 2.0–3.0% w/w loss on drying and milled to a particle size between 180 µm and 850 µm. The process deliberately avoids pre-pelleting addition because exposure to feed conditioning at 80°C for 40 s reduces assay by 2–4% in uncoated granules; post-pelleting dry dosing or post-conditioning liquid addition is preferred. Compliance for this segment references 21 CFR Part 225 and 21 CFR Part 226 for medicated feed manufacturing, ISO 6497:2002 for sampling, ISO 4833-1:2013 for enterobacteriaceae and total viable count, and VICH GL18 for residual solvents. Finished product types include 1.0% w/w feed granules, 0.5% w/w top-dress powders, and 5.0% w/w intermediate premix for further dilution by feed mills. A specific limitation is incompatible combination with alkaline mineral mixes containing more than 3.0% w/w calcium oxide or sodium bicarbonate, which raises local pH above 8.5 and accelerates hydrolysis in stored complete feed.

Broiler drinking water solutions and premix compatibility

In broiler integrators where water medication is used, Halimide Veterinary Grade API is prepared as a water-soluble powder at 20.0% w/w active content and administered in drinking water at 0.02–0.05% w/v final medicated water concentration. The powder is manufactured in a low-shear paddle mixer of 500 kg capacity using a citric acid–sodium bicarbonate effervescent couple at 35.0% w/w and lactose monohydrate at 44.5% w/w; the effervescent system ensures dispersion within 5 min in water at 15–20°C without high-shear mixing. Dissolution and dispersion are tested using Ph. Eur. 2.9.3, and finished water solubility is checked by measuring residue after passing through a 0.45 µm filter. Residual solvent limits are controlled under VICH GL18; the marketing authorisation file follows EU Regulation 2019/6 for veterinary medicinal products. The finished product types are 20.0% w/w water-soluble powder and 0.05% w/v drinking water solution prepared on farm. A critical process boundary is acidification of drinking water with organic acids below pH 5.5, which causes the active to precipitate as free acid and reduces recovered concentration by up to 18% after 2 h; water chlorination above 2 ppm free chlorine is also avoided because oxidative degradation produces two unidentified non-active peaks in HPLC analysis. Stability studies under VICH GL11 show that the soluble powder in aluminium-foil sachets remains within specification for 24 months at 25°C/60% RH but drops to 6 months at 40°C/75% RH.

When Halimide Veterinary Grade API is compressed into tablets or filled into capsules for companion animal dosing

Companion animal dosage forms based on Halimide Veterinary Grade API require wet granulation because the API batch density is typically 0.35 g/mL and flow through a 2 mm funnel is insufficient for direct compression. A representative 50 mg tablet consists of Halimide 25.0% w/w, lactose monohydrate 60.0% w/w, microcrystalline cellulose 10.0% w/w, croscarmellose sodium 4.0% w/w, and magnesium stearate 1.0% w/w. Granulation uses povidone K30 as a 5.0% w/v binder solution in isopropanol–water 1:1, added at 10–12% w/w; drying in a fluid bed at 55–65°C continues until loss on drying is 1.5–2.5% w/w. Compression on a rotary press runs at 35–50 rpm with a compression force of 14–18 kN, target hardness 80–120 N, friability <1.0% per USP <1216>, and disintegration <15 min per USP <2040>. Capsule filling for a 50 mg capsule in size 2 gelatin shells uses the same granulate, with sodium lauryl sulfate 0.5% w/w added intragranularly to improve wetting; fill weight is 200 mg and uniformity of dosage units is tested under USP <905>. Dissolution acceptance is Q=75% in 45 min using USP <711> apparatus 2 at 50 rpm in 900 mL of pH 6.8 phosphate buffer. Finished product types are 50 mg tablets and 50 mg immediate-release capsules for companion animal species where local marketing authorisation provides an indication, packaged in PVC/PE/PVDC blister strips with aluminium foil. In high-humidity facilities where ambient relative humidity exceeds 60%, sticking and picking during compression cannot be controlled by magnesium stearate alone; the granulation suite is therefore maintained at 45±5% RH and 20±2°C to prevent water uptake above 2.0% w/w in the final blend.

Granule and powder line design under high-humidity tropical conditions

Production of Halimide Veterinary Grade API granules and powders in tropical sites with ambient humidity above 75% is constrained by the blend’s hygroscopic behaviour and requires dehumidified suites with supply air at 22±2°C and 45±5% RH. A dry powder for reconstitution into oral solution is prepared at 10.0% w/w Halimide, mannitol 70.0% w/w, sodium citrate 10.0% w/w, xanthan gum 2.0% w/w, and sucralose 0.1% w/w; the powder is blended in a low-shear paddle mixer at 10 rpm for 20 min, then vacuum-dried at 40–45°C under -0.08 MPa for 4 h before sifting through a 355 µm sieve. The environment is classified as ISO 14644-1 Class 8 for non-sterile powder operations, and moisture is tested under ISO 6496:1999 with acceptance below 5.0% w/w. The addition ratio for this oral powder is 10.0% w/w, and the reconstituted solution is typically diluted 1:200 into drinking water for swine or poultry according to local prescription. The finished product types include 10.0% w/w granules for reconstitution and 5.0% w/w oral powders in single-dose sachets. A production bottleneck observed in these conditions is caking of the spray-dried mannitol when residual moisture exceeds 6.0% w/w, which increases tapped density from 0.45 g/mL to 0.62 g/mL and blocks the sieve; sacks are therefore opened only in the dispensed booth and bulk material is never stored overnight. Any deviation above 50% RH during packaging is corrected by increasing nitrogen purge in the aluminium-lined sachet to 0.4 L/min.